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AMPA receptor antagonists. Indeed, different com-
petitive (8) or non-competitive (9,10) AMPA recep-
tor inhibitors have been reported to prolong the 
survival of transgenic (Tg) mice with mutant Cu/Zn 
superoxide dismutase (SOD1) when administered 
before the onset of motor impairment. Using the 
non-competitive AMPA receptor inhibitor, we mod-
estly reduced the loss of MNs in the lumbar spinal 
cord of SOD1-G93A mice, while the morphology of 
the remaining MNs, and especially that of the den-
drites was well preserved by the treatment (9). As 
AMPA receptor-mediated excitotoxicity on MNs in 
in vitro paradigms is thought to be mediated by an 
excessive calcium inﬂ  ux particularly at the level of 
the dendrites, we hypothesized that the beneﬁ  cial 
effect of AMPA receptor inhibitors could be a result 
of a reduced permeability to calcium. The drug used 
in our previous study belongs in the class of active 
    Introduction 
  Amyotrophic lateral sclerosis (ALS) is a multifac-
torial (1), multisystem (2), non-cell autonomous 
disease (3). Several pathomechanisms of the degen-
eration of motor neurons (MNs) have been identi-
ﬁ   ed, which contribute to the progression of the 
motor dysfunction during the disease. Excitotoxicity 
has attracted considerable attention since an abnor-
mal glutamate metabolism was documented in 
pathogenesis-oriented clinical studies (4), and was 
conﬁ   rmed in in vitro experiments and in animal 
models of ALS (5). Moreover, riluzole, the only drug 
to date to display a potential to increase patient sur-
vival, has an anti-excitotoxic effect (6). Since glutamate-
induced excitotoxicity to MNs is mediated through 
calcium-permeable alpha-amino-3-hydroxy-5-methyl-
4-isoxazolepropionic acid (AMPA) receptors (7), a 
protective effect was expected from treatment with 
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  Abstract 
  We tested the efﬁ  cacy of treatment with talampanel in a mutant SOD1 mouse model of ALS by measuring intracellular 
calcium levels and loss of spinal motor neurons. We intended to mimic the clinical study; hence, treatment was started when 
the clinical symptoms were already present. The data were compared with the results of similar treatment started at a 
presymptomatic stage. Transgenic and wild-type mice were treated either with talampanel or with vehicle, starting in pre-
symptomatic or symptomatic stages. The density of motor neurons was determined by the physical disector, and their 
intracellular calcium level was assayed electron microscopically. Results showed that motor neurons in the SOD1 mice 
exhibited an elevated calcium level, which could be reduced, but not restored, with talampanel only when the treatment 
was started presymptomatically. Treatment in either presymptomatic or symptomatic stages failed to rescue the motor 
neurons. We conclude that talampanel reduces motoneuronal calcium in a mouse model of ALS, but its efﬁ  cacy declines 
as the disease progresses, suggesting that medication initiation in the earlier stages of the disease might be more effective.   
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non-competitive antagonists (or negative allosteric 
modulators) of the AMPA subtype of glutamatergic 
excitatory amino acid receptor inhibitors similar 
to talampanel (8-methyl-7H-1,3-dioxolo(2,3)benzo-
diazepine) (10). 
  Talampanel, an orally active drug, was recently 
selected for a clinical trial (11), which unfortunately 
did not meet the expected efﬁ  cacy in reducing the 
disease-related functional deterioration in ALS 
patients. In an attempt to resolve the mismatch 
between the results of the animal studies and the 
clinical trial we tested the efﬁ   cacy of talampanel 
treatment by direct assay of the intracellular calcium 
level and the number of surviving spinal MNs in 
mutant SOD1 Tg mice in presymptomatic and 
symptomatic age groups.     
  Methods   
  Animals 
  Hemizygous Tg mice, expressing mutant human 
SOD1 with a G93A substitution, obtained originally 
from Jackson Laboratories, were bred and main-
tained in a C57BL/ 6JOlaHsd mice strain at the 
  ‘  Mario Negri ’   Institute for Pharmacological Research, 
Milan, Italy. The animals were housed at a tempera-
ture of 21°    C under a 12-h dark/light cycle. Food 
(standard pellets) and water were supplied ad libi-
tum. Female mutant SOD1 Tg mice were treated 
orally with talampanel (5 mg/kg body weight dis-
solved in 0.1 ml Tween 80) or with vehicle only once 
a day for two weeks. The oral 5 mg/kg dose of talam-
panel was selected on the basis of no observed adverse 
effect on body weight gain (TEVA, personal com-
munication) and on a pilot study in our laboratory 
showing that this dose was effective in ameliorating 
mitochondrial functionality in mutant SOD1 Tg 
mice (unpublished data). Animals were treated at the 
same hour in the morning every day, without anaes-
thesia, by direct administration into the lower oesoph-
agus by using an appropriate stainless steel gavage 
needle with a round tip. Treatments were started at 
10 or 17 weeks of age, i.e. ages corresponding to the 
presymptomatic stage and to the onset of the motor 
dysfunction. Age-matched female non-Tg mice that 
were treated similarly were used as controls. Proce-
dures involving animals and their care were con-
ducted in full conformity with the institutional 
guidelines, which are in compliance with national 
(D.L. No. 116, G.U. Supplement 40, February 18, 
1992, Circolare No. 8, G.U., 14 luglio 1994) and 
international (EEC Council Directive 86/ 609, OJ L 
358, 1 DEC.12, 1987; NIH Guide for the Care and 
Use of Laboratory Animals, United States National 
Research Council, 1996) laws and policies.     
  Specimen preparation 
  Under terminal anaesthesia with Equitensin 
(1% phenobarbital, 4% (v/v) chloral hydrate; 6   μ  l/g, 
  intraperitoneally), mice in the two age groups (at 
12 weeks or 19 weeks of age;   n        12 in each group) 
were perfused transcardially with a glutaraldehyde 
ﬁ  xative containing potassium oxalate for simultane-
ous preservation of the ultrastructure and precipita-
tion of the tissue calcium, described in detail earlier 
(12). Transverse slices 2  –  3 mm in thickness were 
removed from lumbar segments of the spinal cords 
and processed by the oxalate-pyroantimonate method 
for visualization of the tissue calcium electron micro-
scopically as electron-dense deposits (EDDs) (12). 
From the same plastic-embedded tissue blocks, 
series of ultra-thin (thickness 50 nm) and semi-thin 
(thickness 300 nm) sections were prepared to deter-
mine the volume density of the EDDs in the lumbar 
MNs under the electron microscope, and to assay the 
numerical density of these cells light microscopically.     
  Quantiﬁ  cation of the calcium level and 
the volume density of MNs 
  The level of calcium in the perikaryonal region of 
the MNs was considered to be reﬂ  ected by the vol-
ume density of the EDDs and was determined by 
point-counting methods in electron microscopic 
prints. The technique was adapted to neural tissue 
in an earlier study (13). Pooled data were expressed 
as percentages of the perikaryonal volume occupied 
by the EDDs. An unbiased estimation of the number 
of MNs in the lumbar segment of the spinal cord 
was performed by using the physical disector, opti-
mized for sampling such cells in our earlier experi-
ments (14). Pairs of 300-nm-thick toluidine 
blue-stained sections, cut at a distance of 8   μ  m, were 
used for the study. Data were expressed as cell num-
bers in mm  3   of spinal cord tissue for each animal. 
  The cell numbers and the relative volumes of the 
EDDs in the treatment groups were expressed as 
means      SEM. The effects of treatment in the two 
strains were evaluated by two-way ANOVA with 
Duncan post hoc comparison for the two age 
groups.       
  Results 
  In parallel with the morphological signs of degen-
eration, a higher number of EDDs, reﬂ  ecting  an 
increased level of calcium, was seen in the cytoplasm 
of the surviving MNs of the mutant SOD1 Tg ani-
mals compared with wild-type ones (Figure 1). The 
treatment with talampanel reduced the elevated cal-
cium level to a signiﬁ  cant extent, but only in the 
group aged 12 weeks (Figure 2A, B). At this age, a 
62% increase (5.57        0.37% vs. 3.45       0.24%; 
Figure 2A) in the volume density of the EDDs was 
noted in the vehicle-treated Tg animals relative to 
the similarly treated wild-type mice (  p       0.0002). 
This elevated calcium level was reduced by a 
signiﬁ   cant 22% by talampanel treatment (to 
4.33     0.39%;   p        0.01) (Figure 2A), although this 342     M. Paizs et al.     
level was still signiﬁ  cantly higher than that for the 
wild-type group (3.02      0.21%;  p       0.009) (Figure 2A). 
At 19 weeks of age, the MNs from the vehicle-treated 
mutant SOD1 Tg mice displayed similar increases in 
the volume density of the EDDs to those from the 
12-week-old animals relative to the wild-type mice 
(5.13      0.70% vs. 3.15       0.39%;   p       0.014)  (Figure 
2B), but a comparison with the corresponding 
talampanel-treated mutant SOD1 Tg mouse group 
demonstrated that talampanel was non-effective 
(4.88     0.13%;   p        0.721) (Figure 2B). 
  With regard to the number of surviving MNs 
at the age of 12 weeks, the difference between 
the talampanel- and vehicle-treated groups was 
not signiﬁ   cant either in the mutant SOD1 Tg 
group (1.524      0.104 and 1.899      0.107;  p       0.183) 
(Figure 3A), or in the wild-type group (2.161     
 0.078 and 2.396      0.310;  p       0.398) (Figure 3A). At 
the age of 19 weeks, the differences in the mutant 
SOD1 Tg group (1.222        0.083 and 1.537       0.037; 
  p        0.093) (Figure 2B) and the wild-type group 
(2.166      0.142 and 2.041       0.229;   p       0.488) 
(Figure 2B) were likewise not signiﬁ  cant. 
  Disregarding the non-signiﬁ  cant effect of talam-
panel on the number of MNs, the mutant SOD1 Tg 
and wild-type mouse strains were compared directly 
in both age groups. This comparison revealed an 
overall cell loss of 25% at 12 weeks of age in the 
mutant SOD1 Tg animals relative to the wild-type 
controls, before any motor deﬁ   cit was detectable, 
and the MN loss rose to 35% at 19 weeks of age 
(  p        0.005 and   p        0.0001, respectively; one-way 
ANOVA with Duncan post hoc comparison).     
  Discussion 
  Since no signiﬁ  cant effect of talampanel on the num-
ber of MNs could be demonstrated in either of the 
mouse strains in the present study, we pooled the 
numerical density data for the mutant SOD1 Tg and 
wild-type strains in the two age groups. The com-
parison with non-Tg littermates revealed an overall 
   
Figure 1.         Increased calcium level in the lumbar motor neurons of mutant SOD1 Tg mice. An increased number of electron-dense 
deposits (EDDs; arrows) is noted, reﬂ  ecting the distribution of calcium in the motor neurons in the talampanel-treated (A) and the 
vehicle-treated (B) mutant SOD1 Tg mice at the age of 19 weeks. Motor neurons from the wild-type mice at the same age contain 
fewer deposits, regardless of whether they were treated with talampanel (C) or with vehicle only (D). Besides the increased number 
of EDDs in the mutant SOD1 Tg animals, mitochondrial degeneration with clusters of EDDs (asterisk) was frequently seen. In the 
wild-type animals, regardless of the treatment, no structural alterations were present. Mit: mitochondrion, Go: Golgi complex. Bar: 
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cell loss of 25% at 12 weeks of age in the mutant 
SOD1 Tg animals, before any motor deﬁ  cit  was 
detectable. At 19 weeks of age, the mutant SOD1 Tg 
mice exhibited a decline of about 50% in their grip 
strength (15), which may be compared with a 35% 
cell loss obtained in our experiments, since even at 
a late symptomatic stage the reported loss of MNs 
does not exceed 50% (16). Otherwise, our ﬁ  nding 
that talampanel itself had no effect on the number 
of spinal MNs in the wild-type mice suggests that 
the drug (at the applied dose) may safely be used in 
these animals. 
  In accordance with the ﬁ   rst description of an 
altered calcium level in the MNs of mutant SOD1 
Tg animals (17), a higher calcium level was detected 
in the surviving MNs compared with the wild-type 
mice. Our empirical approach to quantify the relative 
amount of EDDs as proportional to the concentra-
tion of intracellular calcium is based on the 
cytochemical precipitation of calcium as EDDs, and 
visualization of the EDDs under the electron micro-
scope. Comparable techniques in the literature, based 
on calcium precipitation with oxalate-pyroantimonate 
(18,19), bichromate (20), or phosphate-chromium(III)-
trisoxalate (21), probably reveal a fraction of the 
mobile, or loosely bound calcium (21). In this study, 
a glutaraldehyde ﬁ  xative containing oxalate anions 
was employed to conserve the distribution of cal-
cium and preserve the structure for electron micros-
copy (18,19). The method for the quantiﬁ  cation of 
the distribution of calcium, based on identiﬁ  cation 
of the pattern of EDDs with that of calcium, was 
conﬁ  rmed in earlier experiments, and proved useful 
for following slowly-evolving function-dependent 
changes in the intracellular calcium in a variety of 
experimental paradigms (22  –  26), including the ﬁ  rst 
description of an increased calcium level in the motor 
nerve terminals in muscle biopsies from ALS patients 
(27) and in the MNs of mutant SOD1 Tg animals 
(17); it was also suitable in the present study for an 
assessment of the effect of talampanel on the calcium 
level of the MNs. 
  The demonstrated effect of talampanel in reduc-
ing motoneuronal calcium if applied presymptom-
atically suggests that the rationale of the treatment is 
basically correct. However, the lack of any effect at 
the symptomatic stage indicates that the drug loses 
its efﬁ   cacy as the disease progresses. Nonetheless, 
even though talampanel was effective in reducing the 
level of intracellular calcium in the presymptomatic 
stage, no effect was seen on the rescue of surviving 
MNs, and this may provide a hint that talampanel 
 
  Figure 2.         Effects of talampanel treatment on the calcium level 
of lumbar motor neurons of mutant SOD1 Tg mice. The volume 
occupied by electron-dense deposits (EDDs), reﬂ  ecting tissue 
calcium, relative to the perikaryal volume was determined in 
mutant SOD1 Tg (mSOD1-Tg) and wild-type (wt) animals after 
talampanel (Ta) or vehicle (Ve) treatment at 12 (A) and 19 
(B) weeks of age. Talampanel had a signiﬁ  cant effect in reducing 
the calcium level only at the age of 12 weeks (asterisk;   p       0.01, 
two-way ANOVA with Duncan post hoc comparison). Data are 
shown as means       SEM.  
   
Figure 3.         Effects of talampanel treatment on the number of 
lumbar motor neurons in mutant SOD1 T g mice. Relative to 
the vehicle-only treatment (Ve), talampanel treatment (Ta) did 
not exert a signiﬁ  can t  e ff ect  ei th er  in  th e  m u tan t  S O D 1  T g  
(mSOD1-Tg), or in the wild-type (wt) mice in the presymptomatic 
(A) or a later stage of the disease (B). Regardless of the 
treatment, lower cell numbers were counted at 19 weeks of age 
than at 12 weeks of age in the mutant SOD1 Tg animals. Data 
are shown as means       SEM.  344     M. Paizs et al.     
actually exerts its expected effect, but is overwhelmed 
by the increasing pathogenic mechanisms. Thus, the 
ultimate failure of treatment with talampanel may 
possibly be attributed, at least in part, to the late 
initiation of the medication relative to the disease 
progression and/or to the lack of supplementation 
with other drugs compensating additional compo-
nents of the pathomechanism. These results under-
score the importance of estimation of the efﬁ  cacy of 
drug action in both the presymptomatic and symp-
tomatic phases during preclinical animal experiments 
(28), and accentuate the need for early diagnostic 
biomarkers for ALS which may facilitate clinical trials 
and will presumably allow earlier initiated and more 
efﬁ  cacious therapy (29).     
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